The specter of generic rivalry has consistently loomed over copyright’s blockbuster drug, Viagra, raising questions about the future of connected medicinal ventures. While initial times saw impressive returns, the exclusivity lapse has allowed the way for discounted substitutes, possibly reducing revenue and creating a real danger for stakeholder